Build the future of aesthetic medicine
A scalable platform for delivery of total aesthetic solutions. We are focused on patient retention through technology-driven precise treatment pathways.
A new infrastructure layer for aesthetic medicine
Precision-driven aesthetic treatment, guided by digital imaging
EFx is an integrated technology platform for the delivery of aesthetic treatments, based on computer-guided imaging of the patient’s face.
By combining smartphone-based LiDAR facial mapping, stable anatomical reference points and proprietary sizing algorithms, EFx translates established injection protocols into a standardised, digital system.
At the centre is a proprietary, disposable delivery device designed to standardise site selection and dosing at scale.
Platform Model
A scalable platform for delivery of aesthetic solutions
EFx combines smartphone-based 3D facial mapping, stable anatomical reference points and clinically derived algorithms to translate established injectable protocols into a more standardised, scalable treatment pathway. Early research suggests the platform may contribute to expansion of the overall aesthetic market by improving accessibility and engaging consumer groups who may not have previously interacted with these treatments. There is also potential for more streamlined delivery, with associated efficiencies and cost benefits across treatment pathways.
Protocol Digitisation
Established treatment protocols are converted into a structured digital framework, supporting more consistent site selection and dosing logic across approved indications.
Scalable Patient Pathway
EFx enables a digitally supported treatment journey spanning onboarding, education, consent and prescribing, creating a more efficient model for patient access and program delivery.
Standardised Delivery Model
The platform is designed to reduce variability in treatment execution through algorithm-informed mapping and a simple disposable delivery device, helping support consistency at scale.
Commercial Expansion Potential
While the initial protocol focuses on glabellar lines, EFx is supported by a growing IP portfolio, including two granted and one pending US patents, alongside a proprietary algorithm for injection mask sizing and allocation. Combined with deep industry expertise and a planned proof-of-placement trial in Q3 2026, the platform is positioned for expansion across additional treatment areas and injectable applications.
Platform Value
Designed to support ongoing engagement beyond a single treatment event
EFx is intended to operate beyond an individual procedure as a longitudinal treatment platform. By maintaining a digital record of the face and neck over time, the system can support monitoring of anatomical change, including visible changes associated with ageing such as volume loss.
Longitudinal Data Capture
The platform supports ongoing facial recordkeeping, enabling a structured view of change over time and creating a stronger foundation for treatment pathway continuity.
Relevant Treatment Pathways
Clinically relevant prompts and education can be delivered in line with evolving patient needs, helping guide the next stage of treatment within an approved care framework.
Provider Network Integration
The EFx ecosystem can support connection to affiliated clinics, prescribing models and provider networks, strengthening patient flow and integration across care networks.
Built for Scale
A growing market. A structured platform.
The global cosmetic injectables market was valued at approximately $13 billion in 2024 and is projected to reach ~$40 billion by 2034. Source: McKinsey & Company and industry reports
Global market value in 2024
Projected market by 2034
EFx is positioned as both
Protected for long-term growth
EFx holds granted and pending US patents covering data capture, sizing algorithms, device design, and broader applications across injectable agents and treatment areas — supporting long-term scalability and continued platform development.